Grey Wolf Therapeutics

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. THey are targeting the endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target.

show less